Risk of Thyroid Cancer Associated with Use of Liraglutide and Other Antidiabetic Drugs in a US Commercially Insured Population
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Quantify association between the glucagon-like peptide-1 receptor agonist liraglutide and risk of thyroid cancer (TC) compared to other antidiabetics. PATIENTS AND METHODS: Initiators of liraglutide, exenatide, metformin, pioglitazone or groups of dipeptidyl peptidase-4 inhibitors or sulfonylureas were identified in a US health plan (2010-2014) and followed for a median of 17 months. Thyroid cancer cases during follow-up were identified via a validated algorithm. Incidence rates of TC among liraglutide and comparators were assessed using relative risks estimated within propensity score-matched cohorts using intention to treat (ITT) and time on drug analyses. Latency effects and potential surveillance bias were evaluated. RESULTS: Relative risks from ITT analyses ranged from 1.00 (95% confidence interval (CI) 0.56-1.79) versus metformin to 1.70 (95% CI 1.03-2.81) versus all comparators excluding exenatide. Effect estimates from latency analyses were slightly attenuated. Time on drug analyses suggested no increased risk for either longer duration or higher cumulative dose of liraglutide. Medical record review found 85% were papillary or a follicular variant of papillary or both; 46% were microcarcinomas (≤10 millimeters), which were more prevalent in the liraglutide cohort (67% versus 43% in all comparators). CONCLUSION: Relative risks were elevated for several comparisons, which should be interpreted cautiously because of potential residual confounding and surveillance bias. Liraglutide cases had smaller thyroid nodules and shorter time-to-diagnosis, suggesting increased surveillance for TC among liraglutide initiators, especially shortly after the drug´s approval. After adjusting the primary analyses (ITT) for latency, no significant elevated risk of TC was observed among liraglutide initiators.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additional analysis including intention to treat with latency (exclusion of cases in the first year), time on drug, and cumulative exposure to the drug, failed to reach a statistically significant difference.38”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [38]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Two studies reported statistically significant findings of increased risk for thyroid cancer in those exposed to GLP-1 RA.25,38”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [38]
The cited source says what the claim attributes to it.
In the citing paper
“Similarly, claims for thyroid-related tests, imaging, diagnostic procedures, or presence of goiters/nodules was similar between the liraglutide initiators and all other comparators groups (49.8% vs. 48.5%).38”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [38]
The cited source says what the claim attributes to it.
In the citing paper
“Micropapillary thyroid cancer represented 46% of the cases, with a proportion of 67% of the cases of liraglutide initiators (6/9), 50% of cases of exenatide initiators (1/2), and 43% of all comparators (27/63).”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [38]
The cited source says what the claim attributes to it.
In the citing paper
“In addition, five studies included analyses considering different lag times for outcome assessment, while two studies provided distinct information differentiating between thyroid cancer in general and MTC.25,38,51–53”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [38]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The central role of the propensity score in observational studies for causal effects
ROSENBAUM, P. R., & RUBIN, D. B. (1983) · Biometrika · doi:10.1093/biomet/70.1.41 · Cited by 31,241
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“Even the relatively large Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial could not achieve sufficient power to analyze TCs (5 TC cases with liraglutide and 3 with placebo).(31) Intention to treat, TOD, and latency analyses were conducted in this study, and result…”
ResultWells, S. A., Asa, S. L., Dralle, H., Elisei, R., Evans, D. B., Gagel, R. F., Lee, N., Machens, A., Moley, J. F., Pacini, F., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0335 · Cited by 2,444
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Roberts, A. W., Davids, M. S., Pagel, J. M., Kahl, B. S., Puvvada, S. D., Gerecitano, J. F., Kipps, T. J., Anderson, M. A., Brown, J. R., Gressick, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1513257 · Cited by 1,900
Evaluating medication effects outside of clinical trials: new-user designs
Ray, W. A. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg231 · Cited by 1,646 · cited 1×
“In this paper, results of the primary analyses of the FDA post-marketing requirement are presented where the relationship between liraglutide and TC relative to several matched comparison groups initiating other ADs was quantified, using a new-user, active-comparator study design within a well-defined population.(11,1…”
MethodWorldwide Thyroid-Cancer Epidemic? The Increasing Impact of Overdiagnosis
Vaccarella, S., Franceschi, S., Bray, F., Wild, C. P., Plummer, M., & Dal Maso, L. (2016) · New England Journal of Medicine · doi:10.1056/nejmp1604412 · Cited by 1,145
Schneeweiss, S., Rassen, J. A., Glynn, R. J., Avorn, J., Mogun, H., & Brookhart, M. A. (2009) · Epidemiology · doi:10.1097/ede.0b013e3181a663cc · Cited by 1,128 · cited 1×
“Matching has also been shown to control for potential confounding in studies using claims data where markers for confounders are missing or incomplete.(34,35) Additionally, TC cases were identified using an ORD-validated algorithm with a high PPV, rather than relying on a single ICD-9 code.”
MethodMatching Using Estimated Propensity Scores: Relating Theory to Practice
Rubin, D. B., & Thomas, N. (1996) · Biometrics · doi:10.2307/2533160 · Cited by 1,074
Matching Using Estimated Propensity Scores: Relating Theory to Practice
Thomas, N. (2006) · Matched Sampling for Causal Effects · doi:10.1017/cbo9780511810725.024 · Cited by 1,018
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944 · cited 8×
“Generalized estimating equations (GEE) with exchangeable correlation structures and robust variance estimators accounted for the paired nature of the data created by matching, except where data were too sparse to support GEE.23 In a latency analysis, person-time and TC cases from the first year of follow-up were exclu…”
BackgroundInfluential
Research works printed but not linked: 1
- Parsons LS. Reducing bias in a propensity score matched-pair sample using greedy matching techniques. Paper 214-26 in proceedings of the twenty-sixth annual SAS users group international conference. Long Beach, California: SAS Institute, Inc; 2001. Available from: http://www2.sas.com/proceedings/sugi26/p214-26.pdf. Accessed November 01, 2019.
Cited by
Semaglutide and cancer: A systematic review and meta-analysis
Nagendra, L., BG, H., Sharma, M., & Dutta, D. (2023) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102834 · Cited by 86
Glucagon-like peptide 1 receptor agonists and thyroid cancer: is it the time to be concerned?
Lisco, G., Tullio, A. D., Disoteo, O., Piazzolla, G., Guastamacchia, E., Sabbà, C., Geronimo, V. D., Papini, E., & Triggiani, V. (2023) · Endocrine Connections · doi:10.1530/ec-23-0257 · Cited by 50
Dong, S., & Sun, C. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1032199 · Cited by 37
“Currently, most of the warning information about GLP-1RA comes from clinical trials or case reports, and only a limited number of pharmacovigilance studies have explored other adverse reactions of this kind of drug (23, 24).”
BackgroundGlucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review
Espinosa De Ycaza, A. E., Brito, J. P., McCoy, R. G., Shao, H., & Singh Ospina, N. (2024) · Thyroid · doi:10.1089/thy.2023.0530 · Cited by 37
“38 More recently, Bea et al. evaluated the risk for thyroid cancer associated with the use of GLP-1 RA (albiglutide, dulaglutide, exenatide, and lixisenatide) compared with SGLT2 inhibitors, in a population-based cohort study using claims data (Korean National Health Insurance Database) from 2014…”
Approach to the patient with thyroid nodules: considering GLP-1 receptor agonists
Kelly, C. A., & Sipos, J. A. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae722 · Cited by 30
Metadata
- Authors
- Funch, D., Mortimer, K., Ziyadeh, N. J., Seeger, J. D., Zhou, L., Ng, E., Ross, D., Major-Pedersen, A., Bosch-Traberg, H., Gydesen, H., & Dore, D.
- Affiliations
- Harvard University (US)
- Novo Nordisk (Denmark) (DK)
- Brown University (US)
- Corresponding author
- Ziyadeh, Najat J
- Venue
- Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
- Publisher
- Informa UK Limited
- Published
- 2021-06
- Volume
- Volume 14
- Pages
- 2619-2629
- ISSN
- 1178-7007 (ISSN-L)
- PMC
- PMC8203194
- OpenAlex
- W3171649840
- Cited by
- 24
- References
- 37
- Citations by year
- 2026: 6 · 2025: 6 · 2024: 5 · 2023: 5 · 2022: 2
- FWCI
- 0.94
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Diabetes Metabolic Syndrome and Obesity (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- Novo Nordisk
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- liraglutide, thyroid cancer, GLP-1 receptor agonists, exenatide, metformin, pioglitazone, DPP-4 inhibitors, sulfonylureas, antidiabetic drugs, drug safety, papillary thyroid carcinoma, thyroid microcarcinoma, surveillance bias
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Risk of Thyroid Cancer Associated with Use of Liraglutide and Other Antidiabetic Drugs in a US Commercially Insured Population. https://app.cochat.ai/papers/10.2147/dmso.s305496
- The paper
- Funch, D., Mortimer, K., Ziyadeh, N. J., Seeger, J. D., Zhou, L., Ng, E., Ross, D., Major-Pedersen, A., Bosch-Traberg, H., Gydesen, H., & Dore, D. (2021). Risk of Thyroid Cancer Associated with Use of Liraglutide and Other Antidiabetic Drugs in a US Commercially Insured Population. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. https://doi.org/10.2147/dmso.s305496
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

